A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants

European Heart Journal - Cardiovascular Pharmacotherapy

Volumn 3, Issue 1, 2017, Pages 28-36

  Halvorsen, Sigrun ^a,b   Ghanima, Waleed ^b,c   Tvete, Ingunn Fride ^d   Hoxmark, Cecilie ^e   Falck, Pal ^f   Solli, Oddvar ^f   Jonasson, Christian ^g  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c Østfold Hospital   (Norway)

^d NORWEGIAN COMPUTING CENTER   (Norway)

^e BRISTOL MYERS SQUIBB   (United States)

^f PFIZER INC   (United States)

^g NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

Apixaban; Atrial fibrillation; Bleeding; Dabigatran; Non Vitamin K antagonist oral anticoagulants; Oral anticoagulants; Rivaroxaban; Warfarin

Indexed keywords

APIXABAN; DABIGATRAN; RIVAROXABAN; WARFARIN; ANTICOAGULANT AGENT; PRESCRIPTION DRUG; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

ADULT; AGE; AGED; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; BRAIN HEMORRHAGE; CHA2DS2-VASC SCORE; CHRONIC KIDNEY FAILURE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEART FAILURE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; REGISTER; RISK ASSESSMENT; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; INCIDENCE; MULTICENTER STUDY; NORWAY; ORAL DRUG ADMINISTRATION; RETROSPECTIVE STUDY; SURVIVAL RATE; THROMBOEMBOLISM; TRENDS; VERY ELDERLY;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; DABIGATRAN; FEMALE; FOLLOW-UP STUDIES; HEMORRHAGE; HUMANS; INCIDENCE; MALE; NORWAY; PRESCRIPTION DRUGS; PYRAZOLES; PYRIDONES; REGISTRIES; RETROSPECTIVE STUDIES; RIVAROXABAN; SURVIVAL RATE; THROMBOEMBOLISM; WARFARIN;

EID: 85026888862     PISSN: 20556837     EISSN: 20556845     Source Type: Journal    
DOI: 10.1093/ehjcvp/pvw031     Document Type: Article

References (18)

1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke 1991;22:983-988.
2. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857-867.
3. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L, ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-992.
4. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-1151.
5. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM, ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-891.
6. Wettermark B, Zoëga H, Furu K, Korhonen M, Hallas J, Nørgaard M, Almarsdottir A, Andersen M, Andersson Sundell K, Bergman U, Helin-Salmivaara A, Hoffmann M, Kieler H, Martikainen J, Mortensen M, Petzold M, Wallach-Kildemoes H, Wallin C, Sørensen H. The Nordic prescription databases as a resource for pharmacoepidemiological research-A literature review. Pharmacoepidemiol Drug Saf 2013;22: 691-699.
7. Bakken IJ, Nyland K, Halsteinli V, Kvam UH, Skjeldestad FE. The Norwegian patient registry. Nor J Epidemiol 2004;14:65-69.
8. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW, ACC/AHA Task Force Members. AHA/ACC/ HRS guideline for the management of patients with atrial fibrillation: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 2014;130:2071-2104. 2014.
9. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The euro heart survey on atrial fibrillation. Chest 2010;137:263-272.
10. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P, ESC Committee for Practice Guidelines (CPG). Focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012;33:2719-2747.
11. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel userfriendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey. Chest 2010;138:1093-1100.
12. Kaatz S, Ahmad D, Spyropoulos AC, Schulman S, Subcommittee on Control of Anticoagulation. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in nonsurgical patients: Communication from the SSC of the ISTH. J Thromb Haemost 2015;13:2119-2126.
13. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: The R Foundation for Statistical Computing. http:// www.R-project.org/ (10 September 2016).
14. Hylek EM, Held C, Alexander JH, Lopes RD, De Caterina R, Wojdyla DM, Huber K, Jansky P, Steg PG, Hanna M, Thomas L, Wallentin L, Granger CB. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE trial: Predictors, characteristics, and clinical outcomes. J Am Coll Cardiol 2014;63:2141-2147.
15. Halvorsen S, Atar D, Yang H, De Caterina R, Erol C, Garcia D, Granger CB, Hanna M, Held C, Husted S, Hylek EM, Jansky P, Lopes RD, Ruzyllo W, Thomas L, Wallentin L. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: Observations from the ARISTOTLE trial. Eur Heart J 2014;35:1864-1872.
16. Graham DJ, Reichman ME, Wernecke M, Zhang R, Southworth MR, Levenson M, Sheu TC, Mott K, Goulding MR, Houstoun M, MaCurdy TE, Worrall C, Kelman JA. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation 2015;131:157-164.
17. Yao X, Abraham NS, Sangaralingham LR, Bellolio MF, McBane RD, Shah ND, Noseworthy PA. Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation. J Am Heart Assoc 2016;5:e003725.
18. Larsen TB, Skjoth F, Nielsen PB, Kjaeldgaard JN, Lip GY. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: Propensity weighted nationwide cohort study. BMJ 2016;353:i3189.